Multiple Myeloma

There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.

The quadruplet regimen of isatuximab-irfc, carfilzomib, lenalidomide, and dexamethasone elicited a 100% overall response rate and high rates of minimal residual disease negativity in high-risk newly diagnosed multiple myeloma.

Jesus G. Berdeja, MD, further discusses other exciting trials in multiple myeloma and CAR T therapy being presented at the 2020 ASCO Virtual Scientific Program.

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Nearly 5 years after its approval for patients with multiple myeloma, daratumumab is now available in a formulation that can be administered in a fraction of the time required with the original agent.

Sagar Lonial, MD, FACP, discusses some of the remaining challenges to address in the multiple myeloma space.

Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

James Weitzman, MD, discusses sequencing challenges in multiple myeloma treatment.

Faith E. Davies, MD, shares advice on how to best treat patients with relapsed/refractory multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the design of the ongoing phase 3 CANOVA trial in patients with relapsed/refractory t(11;14) multiple myeloma.

Meletios A. Dimopoulos, MD, discusses the evolution of selinexor in multiple myeloma.

Paul G. Richardson, MD, discusses the mechanism of action of CC-92480 in patients with multiple myeloma.

The European Commission has approved subcutaneous formulation of daratumumab for the treatment of patients with multiple myeloma.

Sagar Lonial, MD, FACP, discusses the benefits of early intervention in high-risk smoldering multiple myeloma.

Shaji K. Kumar, MD, discusses the rate of treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

The European Commission has approved isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥2 prior therapies.

An update on the phase 3 OCEAN study of melflufen in relapsed/refractory multiple myeloma reported that patients stayed on treatment longer than had been previously estimated.

Paul G. Richardson, MD, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Saad Usmani, MD, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.

An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.